ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Targeting BCR::ABL1 by means of tyrosine kinase inhibition (TKI) has since resulted in uniquely successful patient outcomes in CML, a result not replicated for most other cancers3.